About tirzepatide
GIP and GLP-1 receptor agonist
Used for
- Type 2 diabetes, alongside diet and exercise
- Weight management in eligible adults, where approved
Usual adult dose
Injected under the skin once weekly. Usually starts at 2.5 mg weekly, increasing gradually; maintenance doses are 5, 10, or 15 mg weekly.
Common side effects
- Nausea, diarrhoea, vomiting, constipation
- Reduced appetite or abdominal discomfort
- Injection-site reactions
- Low blood sugar, especially with insulin or sulfonylureas
Important warnings
- Not for type 1 diabetes or treatment of diabetic ketoacidosis
- Seek urgent care for severe, persistent abdominal pain
- Can cause dehydration from vomiting or diarrhoea
- Tell clinicians before anaesthesia; delayed stomach emptying may increase aspiration risk
Pregnancy
Generally not recommended during pregnancy; contact a clinician if pregnancy occurs. Stop at least one month before planned pregnancy.
Breastfeeding
Information is limited; discuss use with a healthcare professional, as effects on a breastfed infant are uncertain.
Interactions
- Insulin or sulfonylureas can increase low blood sugar risk
- May affect absorption of oral medicines by slowing stomach emptying
- May reduce reliability of oral hormonal contraception during initiation and dose increases
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.